Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy
Purpose Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce an...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/02656736.2024.2304250 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560941371588608 |
|---|---|
| author | Chih-Chung Cheng Hung-Chieh Yeh Pei-Wen Su Chien-Lin Ho Sheng-Chi Chang |
| author_facet | Chih-Chung Cheng Hung-Chieh Yeh Pei-Wen Su Chien-Lin Ho Sheng-Chi Chang |
| author_sort | Chih-Chung Cheng |
| collection | DOAJ |
| description | Purpose Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.Materials and Methods From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.Results Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.Conclusion Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC. |
| format | Article |
| id | doaj-art-1a778063d76c40549d0c2d6143e1e877 |
| institution | Kabale University |
| issn | 0265-6736 1464-5157 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj-art-1a778063d76c40549d0c2d6143e1e8772025-01-03T09:30:27ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572024-12-0141110.1080/02656736.2024.2304250Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapyChih-Chung Cheng0Hung-Chieh Yeh1Pei-Wen Su2Chien-Lin Ho3Sheng-Chi Chang4Department of Surgery, China Medical University Hospital, Taichung, TaiwanDivision of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, TaiwanDepartment of Nursing, China Medical University Hospital, Taichung, TaiwanDivision of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, TaiwanDivision of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, TaiwanPurpose Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.Materials and Methods From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.Results Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.Conclusion Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.https://www.tandfonline.com/doi/10.1080/02656736.2024.2304250Hyperthermic intraperitoneal chemotherapychronic kidney diseaseacute kidney injuryparecoxibcisplatin |
| spellingShingle | Chih-Chung Cheng Hung-Chieh Yeh Pei-Wen Su Chien-Lin Ho Sheng-Chi Chang Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy International Journal of Hyperthermia Hyperthermic intraperitoneal chemotherapy chronic kidney disease acute kidney injury parecoxib cisplatin |
| title | Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy |
| title_full | Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy |
| title_fullStr | Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy |
| title_full_unstemmed | Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy |
| title_short | Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy |
| title_sort | risk factors of chronic kidney disease in cisplatin based hyperthermia intraperitoneal chemotherapy |
| topic | Hyperthermic intraperitoneal chemotherapy chronic kidney disease acute kidney injury parecoxib cisplatin |
| url | https://www.tandfonline.com/doi/10.1080/02656736.2024.2304250 |
| work_keys_str_mv | AT chihchungcheng riskfactorsofchronickidneydiseaseincisplatinbasedhyperthermiaintraperitonealchemotherapy AT hungchiehyeh riskfactorsofchronickidneydiseaseincisplatinbasedhyperthermiaintraperitonealchemotherapy AT peiwensu riskfactorsofchronickidneydiseaseincisplatinbasedhyperthermiaintraperitonealchemotherapy AT chienlinho riskfactorsofchronickidneydiseaseincisplatinbasedhyperthermiaintraperitonealchemotherapy AT shengchichang riskfactorsofchronickidneydiseaseincisplatinbasedhyperthermiaintraperitonealchemotherapy |